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Denervation Systems Have
Distinct Purposes and Different
Technical Requirements
Ahmed et al. report the use of a cardiac electrophysiology ablation
system for renal denervation in a single-center, single-armed,
noncontrolled trial of 10 patients with severe refractory hyperten-
sion (1). Cardiac ablation and renal denervation systems are
designed to comply with distinct and divergent technical require-
ments.
Radiofrequency cardiac ablation systems are required to produce
deep, permanent, scarring lesions of the ventricular myocardium,
necessitating high power levels and risking steam pops and the
formation of char or coagulum. Irrigation is commonly used
because it allows for higher power, deeper or larger lesions, and
minimizes char formation.
In contrast, the renal artery constitutes a radically different
physical environment. The target for ablation is not the whole
thickness of the ventricular wall, but a delicate skein of nerve fibers
in the arterial adventitia (2). Renal artery diameter is an order of
magnitude smaller than any cardiac chamber, and blood flow is an
order of magnitude faster, providing an intense, incessant, natural
irrigation and enabling the most intense heating effect to be
localized away from the lumen.
The extent of tissue damage during radiofrequency ablation is
roughly proportional to both temperature and time. However,
precise temperature control is much more difficult when applying
much larger diameter irrigated electrophysiological electrodes.
This creates the potential for both over- and underablation and the
potential for collateral damage to vital tissues adjacent to the renal
artery, a possibility wholly untested by Ahmed et al. (1). The
Symplicity renal ablation system (Medtronic, Minneapolis, Min-
nesota) delivers a maximum power that is 10-fold lower than
typical cardiac applications. Real-time digital control algorithms
were designed in concert with the specific ablation catheter
electrode that is considerably smaller in length and diameter than
cardiac ablation electrodes. The proprietary control algorithm
analyzes both temperature and impedance to adjust power and is
able to cease all energy application within a thousandth of a second
if feedback is not appropriate. Extensive animal testing and early
human trials have prioritized caution and safety. Yet, it is not clear
from the Ahmed report if appropriate animal testing was per-
formed before human testing.
Immediate damage to the endothelium is inevitable during
denervation, but peer-reviewed laboratory histological data showfully healed endothelium within days, rather than char (3). More-
over, follow-up angiography and renal imaging performed in 2
prospective clinical trials and several single-center investigations
confirm the absence of stenosis and recovery of renal arterial
function following renal denervation therapy (4,5). Even after
clinical application in thousands of patients, the automated algo-
rithm has shown a substantial track record of safety beyond 3 years,
with so far 1 report of renal artery stenosis requiring intervention
(6). This can indeed be improved upon, although claims of
prevention of rare events demand large studies (7).
Concern for risk to patients is admirable, but it should be
followed through logically. Applying nonpurpose-designed abla-
tion systems to the renal artery might be better—or worse—than
conventional care with the Symplicity system and would be wisely
executed within the context of an appropriately designed random-
ized controlled trial designed to address an actual clinical need.
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